Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

MDR software regulations
Impact of MDR Software Regulations on Medical Device Innovation

By João L. Carapinha

May 26, 2026

MDR software regulations under the EU’s Medical Device Regulation (EU 2017/745) are creating heavy operational and financial pressures, according to a survey of 35 SaMD manufacturers listed in the EUDAMED database. Financial burdens hit 88.6 % of respondents at significant or severe levels, while...
GBA-PD therapy development
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...
menstrual health monitoring
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...